Johnson & Johnson (NYSE:JNJ) had its price target lowered by Jefferies Group from $119.00 to $115.00 in a report issued on Tuesday. Jefferies Group currently has a hold rating on the stock.

A number of other research analysts have also recently weighed in on JNJ. Credit Suisse Group AG reiterated a hold rating and set a $112.00 price objective on shares of Johnson & Johnson in a research report on Thursday, May 19th. Morgan Stanley reiterated a hold rating on shares of Johnson & Johnson in a research report on Thursday, May 19th. Bank of America Corp. reiterated a hold rating on shares of Johnson & Johnson in a research report on Thursday, May 19th. Wells Fargo & Co. reiterated a buy rating on shares of Johnson & Johnson in a research report on Wednesday, May 18th. Finally, Deutsche Bank AG reiterated a buy rating on shares of Johnson & Johnson in a research report on Thursday, May 19th. One research analyst has rated the stock with a sell rating, eleven have issued a hold rating and twelve have issued a buy rating to the stock. Johnson & Johnson currently has an average rating of Hold and a consensus price target of $119.10.

Johnson & Johnson (NYSE:JNJ) opened at 118.25 on Tuesday. Johnson & Johnson has a 52 week low of $89.90 and a 52 week high of $126.07. The company has a 50 day moving average of $121.42 and a 200 day moving average of $115.71. The company has a market capitalization of $323.52 billion, a price-to-earnings ratio of 22.04 and a beta of 0.61.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, July 19th. The company reported $1.74 earnings per share for the quarter, topping the consensus estimate of $1.68 by $0.06. Johnson & Johnson had a net margin of 20.97% and a return on equity of 24.70%. The company had revenue of $18.50 billion for the quarter, compared to analysts’ expectations of $17.98 billion. On average, equities analysts forecast that Johnson & Johnson will post $6.69 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 6th. Investors of record on Tuesday, August 23rd were issued a $0.80 dividend. The ex-dividend date of this dividend was Friday, August 19th. This represents a $3.20 annualized dividend and a yield of 2.71%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 60.15%.

In related news, VP Dominic J. Caruso sold 41,146 shares of the stock in a transaction that occurred on Tuesday, July 26th. The shares were sold at an average price of $125.01, for a total value of $5,143,661.46. Following the transaction, the vice president now owns 157,819 shares in the company, valued at approximately $19,728,953.19. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CAO Ronald A. Kapusta sold 2,935 shares of the stock in a transaction that occurred on Friday, July 22nd. The stock was sold at an average price of $125.01, for a total transaction of $366,904.35. Following the completion of the transaction, the chief accounting officer now owns 28,660 shares in the company, valued at approximately $3,582,786.60. The disclosure for this sale can be found here. 0.11% of the stock is currently owned by corporate insiders.

A number of institutional investors have recently modified their holdings of the company. Horizon Investments LLC increased its position in shares of Johnson & Johnson by 0.3% in the second quarter. Horizon Investments LLC now owns 2,349 shares of the company’s stock valued at $285,000 after buying an additional 8 shares during the period. Landmark Financial Advisors LLC increased its position in shares of Johnson & Johnson by 0.5% in the second quarter. Landmark Financial Advisors LLC now owns 1,979 shares of the company’s stock valued at $240,000 after buying an additional 9 shares during the period. Lbmc Investment Advisors LLC increased its position in shares of Johnson & Johnson by 0.4% in the second quarter. Lbmc Investment Advisors LLC now owns 3,764 shares of the company’s stock valued at $457,000 after buying an additional 16 shares during the period. Stratford Consulting LLC increased its position in shares of Johnson & Johnson by 0.6% in the second quarter. Stratford Consulting LLC now owns 3,201 shares of the company’s stock valued at $388,000 after buying an additional 18 shares during the period. Finally, Taylor Wealth Management Partners increased its position in shares of Johnson & Johnson by 1.3% in the second quarter. Taylor Wealth Management Partners now owns 1,505 shares of the company’s stock valued at $183,000 after buying an additional 20 shares during the period. Institutional investors own 65.31% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.

5 Day Chart for NYSE:JNJ

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with Analyst Ratings Network's FREE daily email newsletter.